News Releases

SAN DIEGO, Oct. 10, 2017 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it will present three abstracts on its novel FXR agonist program at the upcoming American Academy for the Study of Liver Diseases (AASLD)

SAN DIEGO, Aug. 15, 2017 /PRNewswire/ -- Metacrine, Inc., an innovative biotechnology company focused on drug development for metabolic diseases, announced it has entered a collaboration with Novo Nordisk A/S to develop Fibroblast Growth Factor 1 ("FGF1") variants for glucose lowering and insulin

SAN DIEGO, April 11, 2017 /PRNewswire/ -- Metacrine, Inc., a leading and innovative biotechnology company focused on drug development for metabolic diseases, announced it will present two abstracts on its novel FXR agonist program at the upcoming International Liver Congress Meeting of the European

SAN DIEGO, Oct. 17, 2016 /PRNewswire/ -- Metacrine, Inc., a leading biotechnology company efficiently developing innovative drugs for metabolic diseases, announced the issuance of a new patent by the U.S. Patent and Trademark Office that supports development for the company's FGF-1 program.

SAN DIEGO, Sept. 14, 2016 /PRNewswire/ -- Metacrine, Inc., a biotechnology company focused on developing innovative therapeutics in metabolic disease through advances in endocrine research, today announced the appointment of Ken Song, M.D., as its new president, chief executive officer and

Appoints Neil McDonnell, CEO, Along with Executive Team and Board San Diego, CA – Metacrine, Inc., a biotechnology company focused on targeting metabolic disease through advances in endocrine research, today announced it has raised $36 million in a Series A financing.